THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM)

EHA Library, Sarah A. Holstein, 387237

MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Sebastian Grosicki, 387238

MAGNETISMM-7: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF ELRANATAMAB VERSUS LENALIDOMIDE IN POST-TRANSPLANT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Maria Victoria Mateos Manteca, 387239

TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Katja Weisel, 387241

BCMA-TARGETED THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION – A SINGLE CENTER EXPERIENCE

EHA Library, Irene Strassl, 387242

TREATMENT PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS

EHA Library, Anita D'Souza, 387243

THE VALUE OF PERIPHERAL BLOOD LYMPHOCYTE SUBSETS IN PREDICTING THE PROGNOSIS OF NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Zhaoyun Liu, 387244

SOCIO-DEMOGRAPHIC FEATURES AND TREATMENT PATTERNS OF MULTIPLE MYELOMA PATIENTS IN SPAIN: AN INTERIM ANALYSIS OF DORIANT STUDY

EHA Library, Marta Grande, 387245

ORAL REGIMEN SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY ASSESSMENT AND OPTIMIZATION

EHA Library, Juan Du, 387246

MONITORING OLIGOSECRETORY MULTIPLE MYELOMA USING MALDI-TOF MASS SPECTROMETRY

EHA Library, Oscar Berlanga, 387247

EVALUATION OF EARLY RELAPSE IN MULTIPLE MYELOMA (MM) PATIENTS

EHA Library, Annita-Ioanna Gkioka, 387248

SERUM OSTEOCALCIN  AS A PREDICTOR FOR THE RISK OF DENOSUMAB AND BISPHOSPHONATE INDUCED HYPOCALCEMIA IN MYELOMA PATIENTS WITH HYPERCALCEMIA

EHA Library, Yuehua Ding, 387249

PROGNOSTIC SIGNIFICANCE AND CLINICAL APPLICABILITY OF THE COMORBIDITY INDICES IN PATIENTS WITH MULTIPLE MYELOMA:  IMWG AND SARC-F SCORE

EHA Library, Nikola Vukosavljevic, 387250

TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA

EHA Library, Christopher J. Ferreri, 387251

IMPACT OF A SIZE OF BONE PLASMACYTOMA ON THE COURSE OF MULTIPLE MYELOMA

EHA Library, Elizaveta Mamaeva, 387252

CHARACTERISTICS AND OUTCOMES OF COVID-19 IN PATIENTS WITH PLASMA CELL DISORDERS DURING THE FIRST OMICRON WAVE IN BEIJING SINCE DECEMBER 2022: A RETROSPECTIVE STUDY AT A TERTIARY CENTER

EHA Library, Xuelin Dou, 387253

CLINICAL FACTORS DETERMINING THE SURVIVAL OF MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE: A SINGLE-CENTER EXPERIENCE

EHA Library, arda bayar, 387254

IMPACT OF OBESITY IN THE CLINICAL OF MULTIPLE MYELOMA PATIENTS: A REPORT FROM MMRF DATASET

EHA Library, Liang Ren, 387255

MINIMAL RESIDUAL DISEASE (MRD) DETECTION TRENDING AS A PRIMARY ENDPOINT IN CERBA RESEARCH MULTIPLE MYELOMA (MM) TRIALS

EHA Library, Rania Gaspo, 387256

CARDIAC AMYLOID REACHING FOR EXTENDED SURVIVAL (CARES) TRIALS: 2 PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PHASE 3 TRIALS ASSESSING CAEL-101 IN PATIENTS WITH MAYO STAGES IIIA/IIIB AL AMYLOIDOSIS

EHA Library, Ashutosh Wechalekar, 387257

CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS

EHA Library, Paolo Milani, 387258

THE CLINICAL PICTURE OF CASTLEMAN DISEASE – A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Karan Kanhai, 387259

IMPACT OF EXTRAMEDULLARY DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: MULTICENTER RETROSPECTIVE ANALYSIS

EHA Library, Rita Costa e Sousa, 387260

THE IMPACT OF DISEASE SEVERITY ON THE CLINICAL AND ECONOMIC BURDEN OF AL AMYLOIDOSIS

EHA Library, Anita D'Souza, 387261

TARGETING NEUROBIOLOGICAL MECHANISMS IN PATIENTS WITH MULTIPLE MYELOMA HAS IMPROVED THEIR PLASMACYTOID DENDRITIC CELLS CD123+, B LYMPHOCYTE MEMORY CELLS CD27+, VAGAL ACTIVITY AND DISTRESS.

EHA Library, Pavel Kotoucek, 387262

CLINICAL AND PROGNOSTIC FACTORS IN MULTIPLE MYELOMA IN THE GOMEL REGION

EHA Library, Zhanna Kozich, 387263

AUTOSCT IN PATIENTS WITH MULTIPLE MYELOMA AND DIALYSIS-DEPENDENT NEPHROPATHY

EHA Library, Ekaterina Karimova, 387264

RELAPSING/REFRACTORY ABDOMINAL WALL EXTRA-MEDULLARY PLASMACYTOMAS DEMONSTRATING A RAPID COMPLETE RESPONSE TO BELANTAMAB MAFODOTIN

EHA Library, Mohamed Ali, 387265

CHARACTERIZATION OF THE IMMUNE RESPONSE DEVELOPED IN PATIENTS WITH MULTIPLE MYELOMA AFTER RECEIVING TWO DOSES OF THE VACCINE AGAINST SARS-COV-2

EHA Library, Laura Perez, 387266

MULTIPLE MYELOMA IN THE ELDERLY: A MONOCENTRIC EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF MONASTIR (TUNISIA)

EHA Library, Bizid Inaam, 387267

BORTEZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IS AN EFFECTIVE REGIMEN FOR PATIENTS WITH RELAPSE AND REFRACTORY AL AMYLOIDOSIS AND MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE

EHA Library, Xuelin Dou, 387268

EVALUATION OF IMMUNE RECONSTITUTION IN MULTIPLE MYELOMA PATIENTS ON MAINTENANCE THERAPY WITH LENALIDOMIDE - THE ROLE OF HEAVYLITE CHAINS

EHA Library, Mariana Miranda, 387269

BORTEZOMIB - CYCLOPHOSPHAMIDE – DEXAMETHASONE (VCD) REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) - EXPERIENCE FROM A RESOURCE CONSTRAINT SETTING IN SOUTH INDIA

EHA Library, Rahmathullah Sulaimankutty Nameera, 387270

EFFICACY AND SAFETY EVALUATION OF IXAZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IN THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Zenghua Lin, 387271

THE CO-REBREATHING METHOD IS A RELIABLE TEST IN DETERMINING THE RED CELL MASS : THE OLD POTS MAKE THE BEST SOUPS.

EHA Library, Nada Maaziz, 387272

PRIMARY MYELOFIBROSIS:  SERUM LACTATE DEHYDROGENASE AS A PREDICTOR OF EARLY LEUKEMIC PROGRESSION

EHA Library, Pedro Moura, 387273

P27: A NOVEL SUBSTRATE OF PDGFR

EHA Library, Carlos Miguel Castillo Giron, 387274

LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA

EHA Library, Yu Han Koh, 387275

POTENTIAL ROLE OF FACTOR XII POLYMORPHISM IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Elizaveta Efremova, 387277

PREVALENCE OF FIP1L1-PDGFRΑ FUSION IN TUNISIAN PATIENTS WITH HYPEREOSINOPHILIA

EHA Library, Nermine Torkhani, 387278

THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS

EHA Library, Natalia Korsakova, 387279

DISSECTING THE MECHANISM OF INTERFERON ALFA (IFNΑ) RESPONSE IN MYELOPROLIFERATIVE NEOPLASM AND IDENTIFICATION OF PREDICTORS OF RESPONSE

EHA Library, Eli Soyfer, 387280

NEXT-GENERATION SEQUENCING IN THE DIAGNOSIS, PROGNOSIS AND FEATURES OF THE COURSE OF THE DISEASE IN PATIENTS WITH PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Anna Kirienko, 387281

MRNA OF MPL AND JAK2 GENES IN PLATELETS IS ASSOCIATED WITH THEIR ASPIRIN RESISTANCE IN MPN PATIENTS

EHA Library, Marina Stolyar, 387282

MULTICENTRE RETROSPECTIVE OBSERVATIONAL STUDY ON PATIENTS WITH MYELOFIBROSIS IN PIEDMONT. ROLE OF INFLAMMATION AND DYSIMMUNITY. MFACTORS STUDY.

EHA Library, Valentina Bonuomo, 387283

EVALUATION OF JAK2 EXON 12 MUTATIONS IN PATIENTS WITH JAK2 (V617F)-NEGATIVE POLYCYTHEMIA VERA

EHA Library, Sahar Khosravi, 387284

ALGORITM OF MOLECULAR GENETIC EXAMINATION OF PATIENTS WITH PH-NEGATIVE CRONIC MYELOPROLIFERATIVE NEOPLASM

EHA Library, Nataliya Shurko, 387285

TREATMENT CHALLENGES OF COEXISTING MYELOID AND LYMPHOID NEOPLASM- A CASE REPORT

EHA Library, Mihailo Smiljanic, 387286

CLINICAL FEATURES, TREATMENT APPROACHES, AND OUTCOMES IN ROSAI-DORFMAN DISEASE: A RETROSPECTIVE ANALYSIS OF 104 PATIENTS

EHA Library, Long Chang, 387287

NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AT DIAGNOSIS IN ESSENTIAL THROMBOCYTEMIA (ET): A NEW PREDICTOR OF THROMBOTIC EVENTS

EHA Library, Alessia Ripamonti, 387288

TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)

EHA Library, Lucia Masarova, 387289

EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT-I AND -II TRIALS

EHA Library, Haifa Kathrin Al-Ali, 387291

MOLECULAR RESPONSE TO INTERFERON IN PREFIBROTIC PRIMARY MYELOFIBROSIS- RETROSPECTIVE SINGLE CENTER STUDY

EHA Library, Emine Kaynak, 387292

ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)

EHA Library, Kai Wille, 387293

PROTON PUMP INHIBITORS ARE SAFE AND EFFECTIVE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA TREATED WITH LOW-DOSE ASPIRIN

EHA Library, Ivan Krecak, 387294

UNUSUAL SITE THROMBOSIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE EXPERIENCE WITH 66 CONSECUTIVE CASES.

EHA Library, Erika Morsia, 387295

COMORBIDITIES PREDICT WORSE PROGNOSIS IN PATIENTS WITH POLYCYTHEMIA VERA

EHA Library, Isidora Arsenovic, 387296

A RETROSPECTIVE MULTI-CENTER STUDY ON DIRECT ORAL ANTICOAGULANT USE IN BCR::ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Mehmet Baysal, 387297

JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS

EHA Library, Yun hui Hwang, 387298

JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Xuefei Ma, 387299

HIGHER JAK2 ALLELE BURDEN IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS IS ASSOCIATED WITH HIGHER PREVALENCE OF CHRONIC KIDNEY DISEASE AND UNFAVORABLE DYNAMICS OF KIDNEY FUNCTION OVER TIME

EHA Library, Marko Lucijanic, 387300

CHARACTERISTICS OF PATIENTS WITH POLYCYTHEMIA VERA:  RESULTS FROM A US ELECTRONIC HEALTH RECORDS DATABASE.

EHA Library, Ronald Hoffman, 387301

CLINICAL IMPACT OF NUTRITIONAL STATUS AND NUTRITIONAL MONITORING IN PRIMARY MYELOFIBROSIS PATIENTS: PRELIMINARY RESULTS OF NUTRIMY STUDY

EHA Library, Margherita Malchiodi, 387302

ADULT LANGERHANS CELL HISTIOCYTOSIS WITH LIVER INVOLVEMENT

EHA Library, Long Chang, 387303

TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

EHA Library, Francesca Palandri, 387304

GEOGRAPHIC CLUSTERING OF ERDHEIM-CHESTER DISEASE IN ITALY AND FRANCE

EHA Library, Francesco Peyronel, 387305

FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS

EHA Library, Martine Allard, 387306

ASSOCIATION OF HIGH PLATELETCRIT WITH THROMBOTIC RISK IN POLYCYTHEMIA VERA DEPENDS ON HEMATOCRIT AND LEUKOCYTE COUNT

EHA Library, Ivan Krecak, 387307

NOVEL PREDICTORS FOR VENOUS AND ARTERIAL THROMBOSIS IN POLYCYTHEMIA VERA

EHA Library, Jelena Ivanović, 387308

INCIDENCE AND PREVALENCE OF MYELOFIBROSIS IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS

EHA Library, Sophia Junker, 387309

HIGH SERUM FERRITIN AT INITIAL DIAGNOSIS IS A PREDICTOR OF BONE MARROW FIBROSIS IN PH NEGATIVE  CHRONIC MYELOPROLIFERATIVE NEOPLASMS

EHA Library, ALDO LEONE, 387310

A MECHANISTIC ABSORPTION AND PHARMACOKINETIC MODEL OF COVALENT BTK INHIBITOR TL-895: INFLUENCE OF FOOD AND ACID REDUCING AGENTS

EHA Library, Martine Allard, 387311

PROGRESSION FACTORS OF MYELOFIBROSIS BASED ON CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROMBOCYTHEMIA: A CHINES TWO-CENTER RETROSPECTIVE STUDY

EHA Library, JIAN HUANG, 387312

NEUTROPHIL–TO-LYMPHOCYTE RATIO IS AN EARLY SCREENING TOOL FOR DIAGNOSIS OF POLYCYTHEMIA VERA

EHA Library, Seug Yun Yoon, 387313

CLUSTER ANALYSIS UNVEILS THE CLINICAL SPECTRUM OF ERDHEIM-CHESTER DISEASE

EHA Library, Francesco Pegoraro, 387314

COMPARISON OF THREE PROGNOSTIC SCORING SYSTEMS FOR THE RISK OF THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA: ANALYSIS OF 190 PATIENTS AT THE UNIVERSITY HOSPITAL OF THE CANARY ISLANDS (1990-2022)

EHA Library, Marta Diaz-Lopez, 387315

DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE : A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA

EHA Library, JIAN HUANG, 387316

ABDOMINAL AORTIC CALCIFICATION IN PATIENTS NEWLY DIAGNOSED WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASM

EHA Library, Myung-Won Lee, 387317

RETROSPECTIVE ANALYSIS OF 45 UNSELECTED PATIENTS WITH HISTIOCYTOSIS CONFIRMS PROGNOSTIC RELEVANCE OF ORGAN INVOLVEMENT: SINGLE‐CENTER EXPERIENCE

EHA Library, Hulya Yilmaz, 387318

CORRELATION BETWEEN HEMORRHAGIC EVENTS AND IPSET SCORE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

EHA Library, Mario Tiribelli, 387319

HYDROXYUREA-INDUCED CUTANEUS ADVERSE EVENTS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: A SINGLE-CENTER EXPERIENCE

EHA Library, AMAIA LOPEZ-PEÑA, 387320

REAL-WORLD RESEARCH OF CLINICAL AND HEMATOLOGIC NEOPLASMS RELATED GENETIC MUTATIONS IN 275 POLYCYTHEMIA VERA PATIENTS

EHA Library, JIAN HUANG, 387321

CHILDHOOD MYELPROLIFERATIVE NEOPLASMS; A SINGLE CENTER EXPERIENCE

EHA Library, Hasanein Ghali, 387322

POLYPHARMACY AND DRUG-TO-DRUG INTERACTIONS MAY HAVE A NEGATIVE EFFECT ON SURVIVAL IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Ivan Krecak, 387323

ATRIAL FIBRILLATION IS FREQUENT IN PATIENTS WITH MYELOFIBROSIS AND MIGHT BE SUB-OPTIMALLY TREATED

EHA Library, Marko Lucijanic, 387324

AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF

EHA Library, Andrew Kuykendall, 387325

DOES LUNG LESION SEVERITY AFFECT THE OUTCOME IN PEDIATRIC PULMONARY MULTISYSTEM LANGERHANS CELL HISTIOCYTOSIS ?

EHA Library, Mohamed Sedky Sedky, 387326

CLINICOPATHOLOGICAL, CYTOGENETIC AND MOLECULAR CHARACTERISTICS OF PATIENTS WITH NON-CML MYELOPROLIFERATIVE NEOPLASMS: A SINGLE CENTER STUDY

EHA Library, Vinay Anand Guntiboina, 387327

ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY

EHA Library, John Mascarenhas, 387328

A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)

EHA Library, John Mascarenhas, 387329

HIGH RISK LANGERHANS CELL HISTIOCYTOSIS (LCH) IN CHILDREN: THE ROLE OF CLADRIBINE SALVAGE IN IMPROVING THE OUTCOME. A SINGLE CENTER EXPERIENCE

EHA Library, Mohamed Sedky Sedky, 387330

TRANSFORMATION OF MYELOPROLIFERATIVE NEOPLASMS INTO ACUTE PROMYELOCYTIC LEUKEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS OF CASE REPORTS

EHA Library, Mihnea-Alexandru Găman, 387331

WHAT IS THE UTILITY OF THE MYSEC-PM ON SECONDARY MYELOFIBROSIS RISK STRATIFICATION IN A REAL LIFE SETTING?

EHA Library, Pedro Moura, 387332

A PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF BENRALIZUMAB IN PATIENTS WITH HYPEREOSINOPHILIC SYNDROME

EHA Library, Priya Jain, 387333

THE ORIGIN IN PRIMARY AND SECONDARY MYELOFIBROSIS: IS THE KEY THE PROGENITOR OR THE MOLECULAR SIGNATURE?

EHA Library, Isabel Montero Cuadrado, 387334

AN OVERLOOKED MIMIC? AUTOIMMUNE MYELOFIBROSIS - A SCOPING REVIEW OF THE LITERATURE

EHA Library, Yosef Joseph Rene Amel Riazat-Kesh, 387335

A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA

EHA Library, Melisa Palacio, 387336

EFFECT OF HYDROXYUREA ON INFLAMMATORY MARKERS IN PATIENTS WITH BCR-ABL NEGATIVE MYELOPROLIFERATIVE DISEASES

EHA Library, Istemi Serin, 387337

DIFFERENTIAL RECOVERY OF MACROPHAGE IRON DEFICIENCY BY ORAL IRON FORMULATIONS DETERMINES CELL INFLAMMATORY ACTIVATION IN ANEMIC CONDITIONS

EHA Library, Francesca Vinchi, 387988

PPP1R1B BINDS IRON REGULATORY PROTEINS AND MODULATES IRON CELLULAR CONTENT

EHA Library, Laura Calvo López, 387989